Epidermal growth factor receptor and Kras gene expression: Reliability of mutational analysis on cytological samples

Diagnostic Cytopathology

Volumn 41, Issue 7, 2013, Pages 595-598

  Bozzetti, Cecilia ^a   Negri, Francesca V ^a   Azzoni, Cinzia ^b   Naldi, Nadia ^a   Nizzoli, Rita ^a   Bortesi, Beatrice ^a   Zobbi, Valentina ^a   Bottarelli, Lorena ^b   Tiseo, Marcello ^a   Silini, Enrico Maria ^b   Ardizzoni, Andrea ^a  

^a UNIVERSITY HOSPITAL OF PARMA   (Italy)

^b UNIVERSITY OF PARMA MEDICAL SCHOOL   (Italy)

Author keywords

colorectal cancer; cytology; EGFR; Kras; lung cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN;

ARTICLE; CLINICAL ASSESSMENT; COLORECTAL CANCER; CYTOLOGY; FINE NEEDLE ASPIRATION BIOPSY; GENE DELETION; GENE EXPRESSION; GENE INSERTION; GENE MUTATION; HISTOLOGY; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; PRIMARY TUMOR; PRIORITY JOURNAL; RELIABILITY;

ADENOCARCINOMA; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; GENE EXPRESSION; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPH NODES; LYMPHATIC METASTASIS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; REPRODUCIBILITY OF RESULTS; TUMOR MARKERS, BIOLOGICAL;

EID: 84879421859     PISSN: 87551039     EISSN: 10970339     Source Type: Journal    
DOI: 10.1002/dc.22905     Document Type: Article

References (23)

1. Cheng L, Zhang S, Alexander R, et al. The landscape of EGFR pathways and personalized management of non-small-cell lung cancer. Future Oncol 2011; 7: 519-541.
2. Allegra CJ, Jessup JM, Somerfield MR, et al. American Society of Clinical Oncology provisional clinical opinion: Testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009; 27: 2091-2096.
3. Malapelle U, Bellevicine C, Zeppa P, Palombini L, Troncone G,. Cytology-based gene mutation tests to predict response to anti-epidermal growth factor receptor therapy: A review. Diagn Cytopathol 2011; 39: 703-710.
4. Billah S, Stewart J, Staerkel G, Chen S, Gong Y, Guo M,. EGFR and KRAS mutations in lung carcinoma: Molecular testing by using cytology specimens. Cancer Cytopathol 2011; 119: 111-117.
5. van Eijk R, Licht J, Schrumpf M, et al. Rapid KRAS, EGFR, BRAF and PIK3CA mutation analysis of fine needle aspirates from non-small-cell lung cancer using allele-specific qPCR. PLoS One 2011; 6: e17791.
6. Fischer AH, Cibas ES, Howell LP, et al. Role of cytology in the management of non-small-cell lung cancer. J Clin Oncol 2011; 29: 3331-3332.
7. Langer CJ, Besse B, Gualberto A, Brambilla E, Soria JC,. The evolving role of histology in the management of advanced non-small-cell lung cancer. J Clin Oncol 2010; 28: 5311-5320.
8. Langer CJ, Besse B, Gualberto A, Brambilla E, Soria JC,. Reply to A.H. Fisher et al. J Clin Oncol 2011; 29: 3332.
9. Hirsch FR, Wynes MW, Gandara DR, Bunn PA, Jr,. The tissue is the issue: Personalized medicine for non-small cell lung cancer. Clin Cancer Res 2010; 16: 4909-4911.
10. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-2139.
11. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-1500.
12. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004; 101: 13306-13311.
13. Bozzetti C, Negri FV, Naldi N, et al. Reliability of K-ras mutational analysis on cytological samples from metastatic colorectal cancer. Pathologica 2011; 103: 77-78.
14. Boldrini L, Gisfredi S, Ursino S, et al. Mutational analysis in cytological specimens of advanced lung adenocarcinoma: A sensitive method for molecular diagnosis. J Thorac Oncol 2007; 2: 1086-1090.
15. Nizzoli R, Tiseo M, Gelsomino F, et al. Accuracy of fine needle aspiration cytology in the pathological typing of Non-Small Cell Lung Cancer (NSCLC). J Thorac Oncol 2011; 6: 489-493.
16. Rekhtman N, Brandt SM, Sigel CS, et al. Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: High accuracy of tumor subtyping and feasibility of EGFR and K-RAS molecular testing. J Thorac Oncol 2011; 6: 451-458.
17. Nicholson AG, Gonzalez D, Shah P, et al. Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, TTF-1, cytokeratin 5/6, and P63, and EGFR mutation analysis. J Thorac Oncol 2010; 5: 436-441.
18. Righi L, Graziano P, Fornari A, et al. Immunohistochemical subtyping of non-small cell lung cancer not otherwise specified in fine-needle aspiration cytology: A retrospective study of 103 cases with surgical correlation. Cancer 2011; 117: 3416-3423.
19. Fassina A, Corradin M, Zardo D, Cappellesso R, Corbetti F, Fassan M,. Role and accuracy of rapid on-site evaluation of CT-guided fine needle aspiration cytology of lung nodules. Cytopathology 2011; 22: 306-312.
20. Malapelle U, de Rosa N, Rocco D, et al. EGFR and KRAS mutations detection on lung cancer liquid-based cytology: A pilot study. J Clin Pathol 2012; 65: 87-91.
21. Malapelle U, de Rosa N, Bellevicine C, et al. EGFR mutations detection on liquid-based cytology: Is microscopy still necessary? J Clin Pathol 2012; 65: 561-564.
22. Troncone G, Malapelle U, Cozzolino I, Palombini L,. KRAS mutation analysis on cytological specimens of metastatic colo-rectal cancer. Diagn Cytopathol 2010; 38: 869-873.
23. Bruno P, Mariotta S, Ricci A, et al. Reliability of direct sequencing of EGFR: Comparison between cytological and histological samples from the same patient. Anticancer Res 2011; 31: 4207-4210.